McGill University - Generic Semaglutide Could Reshape Diabetes Drug Coverage in Canada
3 Articles
3 Articles
The National Agency for Health Surveillance (Anvisa) has granted the Brazilian company EMS the registration of the first generic medicine based on synthetic semaglutide in the country, indicated for the treatment of type 2 diabetes. The product has as reference medicine Ozivy, the first pen based on semimaglutide of national manufacture, developed by the pharmacist and launched in June of this year. Anvisa determines seizure of cosmetics without…
Generic semaglutide could reshape diabetes drug coverage in Canada
Lower-cost medication dramatically improves the cost-effectiveness of treatment that helps prevent heart and kidney disease The arrival of generic semaglutide in Canada significantly improves the cost-effectiveness and affordability of recommended treatments for up to 2.1 million Canadians living with Type 2 diabetes who face a high risk of cardiovascular disease, according to a simulation study led by researchers at McGill University and the Re…
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
